TCR2 THERAPEUTICS INC.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$153.5M | −$99.7M | −$16.2M | −$10.8M | −$4.1M |
| Net income | −$151.8M | −$99.8M | −$15.5M | −$9.9M | −$4.0M |
| Total assets | $208.2M | $323.4M | $246.2M | $168.5M | $129.4M |
| Total liabilities | $67.4M | $41.9M | $9.6M | $8.1M | $5.9M |
| Equity | $140.9M | $281.5M | $236.5M | $160.4M | −$85.7M |
| EPS (diluted) | $-3.93 | $-2.63 | — | — | — |
| Shares out. | 38.5M | 38.1M | 24.1M | 24.0M | 726,990 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −107.8%
- Return on assets
- −72.9%
- Return on capital (ROCE)
- −106.5%
- Liabilities / assets
- 32.4%
- Debt / equity
- 0.48×
- Book value / share
- $3.65
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -7.03distress
- Accruals / assets
- −24.2%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2024-11-19Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
- Phase 1/2Active Not Recruitingreadout ~2028-10-30A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Tang Kevin C10% owner | Jun 1, 2023 | J | 4.4M | — |
| Ubs Oncology Impact Fund L.P.10% owner | Jun 1, 2023 | J | 3.4M | $0.00 |
| Mpm Sunstates Fund, L.P.10% owner | Jun 1, 2023 | J | 4.2M | $0.00 |
| Mpm Bioventures 2014, L.P.10% owner | Jun 1, 2023 | J | 4.2M | $0.00 |
| Gadicke AnsbertDirector | Jun 1, 2023 | J | 304,001 | $0.00 |
| Cardama Alfonso QuintasOfficer — Chief Medical Officer | Jun 1, 2023 | D | 109,459 | — |
| Olagunju PeterOfficer — Chief Operating Officer | Jun 1, 2023 | D | 24,092 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 1, 2023
- Shareholder voteMay 30, 2023
- Entered a material agreementMay 24, 2023
- Other material eventMay 22, 2023
- Results of operationsMay 11, 2023
- Results of operationsMar 23, 2023
- Regulation FD disclosureMar 10, 2023
- Entered a material agreement · Director / officer change · Regulation FD disclosure · Other material eventMar 6, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4Feb 14, 2024
- SC 13G/AAMENDMENT NO. 3Feb 14, 2024
- 15-12GJun 12, 2023
- EFFECTJun 5, 2023
- EFFECTJun 5, 2023
- EFFECTJun 5, 2023
- 4FORM 4 SUBMISSIONJun 5, 2023
- 4FORM 4 SUBMISSIONJun 5, 2023
- 4FORM 4 SUBMISSIONJun 5, 2023
- 4FORM 4 SUBMISSIONJun 5, 2023
- POS AMJun 1, 2023
- POS AMJun 1, 2023
- POS AMJun 1, 2023
- S-8 POSJun 1, 2023
- S-8 POSJun 1, 2023
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.